Request An Appointment
Phone

All Trials

ANEMIA

A Phase 2 Open Label Study Investigating the Efficacy and Safety of Roxadustat (FG-4592) for Treatment of Anemia in Patients Receiving Chemotherapy Treatment for Non-Myeloid Malignancies

BRAIN CANCER

Check back soon for upcoming trials.

BREAST CANCER

A PHASE 1B, MULTICENTER, TWO-PART, OPEN-LABEL STUDY OF DS-8201A, AN ANTI-HUMAN EPIDERMAL GROWTH FACTOR RECEPTOR-2 (HER2)-ANTIBODY DRUG CONJUGATE (ADC), IN COMBINATION WITH NIVOLUMAB, AN ANTI-PD-1 ANTIBODY, FOR SUBJECTS WITH HER2-EXPRESSING ADVANCED BREAST AND UROTHELIAL CANCER

A First-in-Human Phase I Trial to Determine the Safety and the Pharmacokinetic Profile of DSP-0337 in Patients with Advanced Solid Tumors

An Open-label, Nonrandomized, Phase 1 Study to Evaluate the Safety and Pharmacokinetics of Belinostat in Patients with Relapsed/Refractory Solid Tumors or Hematological Malignancies Who Have Wild-Type, Heterozygous, and Homozygous UGT1A1*28 Genotypes

CERVICAL CANCER

A First-in-Human Phase I Trial to Determine the Safety and the Pharmacokinetic Profile of DSP-0337 in Patients with Advanced Solid Tumors

An Open-label, Nonrandomized, Phase 1 Study to Evaluate the Safety and Pharmacokinetics of Belinostat in Patients with Relapsed/Refractory Solid Tumors or Hematological Malignancies Who Have Wild-Type, Heterozygous, and Homozygous UGT1A1*28 Genotypes

CINV (CHEMOTHERAPY INDUCED NAUSEA AND VOMITING)

Check back soon for upcoming trials.

COLON CANCER

A Phase 1b/2, Open-label, Multicenter Study of Novel Oncology Therapies in Combination with Chemotherapy and Bevacizumab as First-line Therapy in Metastatic Microsatellite-stable Colorectal Cancer (COLUMBIA-1)

A First-in-Human Phase I Trial to Determine the Safety and the Pharmacokinetic Profile of DSP-0337 in Patients with Advanced Solid Tumors

An Open-label, Nonrandomized, Phase 1 Study to Evaluate the Safety and Pharmacokinetics of Belinostat in Patients with Relapsed/Refractory Solid Tumors or Hematological Malignancies Who Have Wild-Type, Heterozygous, and Homozygous UGT1A1*28 Genotypes

ESOPHAGEAL CANCER

An Open-label, Nonrandomized, Phase 1 Study to Evaluate the Safety and Pharmacokinetics of Belinostat in Patients with Relapsed/Refractory Solid Tumors or Hematological Malignancies Who Have Wild-Type, Heterozygous, and Homozygous UGT1A1*28 Genotypes

GASTRIC CANCER

An Open-label, Nonrandomized, Phase 1 Study to Evaluate the Safety and Pharmacokinetics of Belinostat in Patients with Relapsed/Refractory Solid Tumors or Hematological Malignancies Who Have Wild-Type, Heterozygous, and Homozygous UGT1A1*28 Genotypes

HEAD AND NECK CANCER

A First-in-Human Phase I Trial to Determine the Safety and the Pharmacokinetic Profile of DSP-0337 in Patients with Advanced Solid Tumors

An Open-label, Nonrandomized, Phase 1 Study to Evaluate the Safety and Pharmacokinetics of Belinostat in Patients with Relapsed/Refractory Solid Tumors or Hematological Malignancies Who Have Wild-Type, Heterozygous, and Homozygous UGT1A1*28 Genotypes

ITP (IDIOPATHIC THROMBOCYTOPENIC PURPURA)

A Randomized, Double-Blind, Placebo-Controlled Study with an Open-Label Extension to Evaluate the Efficacy and Safety of Avatrombopag for the Treatment of Chemotherapy-Induced Thrombocytopenia in Subjects with Active Non-Hematological Cancers

LEUKEMIA

A Phase 3, Randomized, Open-Label, Crossover Study of AsTX727 (Cedazuridine and Decitabine Fixed-Dose Combination) vs IV Decitabine in Subjects with Myelodysplastic Syndromes (MDS) and Chronic Myelomonocytic Leukemia (CMML)

A Randomized, Multicenter, Open-Label, Phase 3 Study to Compare the Efficacy and Safety of Acalabrutinib (ACP-196) in Combination with Venetoclax with and without Obinutuzumab Compared to Investigator’s Choice of Chemoimmunotherapy in Subjects with Previously Untreated Chronic Lymphocytic Leukemia Without del(17p) or TP53 Mutation

               A PHASE 1B STUDY OF PTC299 IN RELAPSED/REFRACTORY ACUTE LEUKEMIAS

A Phase 3, Randomized Study to Assess the Efficacy and Safety of Ublituximab in Combination with TGR-1202 Compared to Obinutuzumab in Combination with Chlorambucil in Patients with Chronic Lymphocytic Leukemia (CLL)

A Phase I/II, Open-Label, Multicentre 2-Part Study to Assess the Safety Tolerability, Pharmacokinetics, and Efficacy of AZD2811 Nanoparticle as Monotherapy or in Combination inTreatment-Naïve or Relapsed/Refractory Acute Myeloid Leukaemia/Myelodysplastic Syndrome Patients Not Eligible for Intensive Induction Therapy

A PHASE III, DOUBLE-BLIND, PLACEBO-CONTROLLED, MULTICENTER, RANDOMIZED STUDY OF PRACINOSTAT IN COMBINATION WITH AZACITIDINE IN PATIENTS ≥18 YEARS WITH NEWLY DIAGNOSED ACUTE MYELOID LEUKEMIA UNFIT FOR STANDARD INDUCTION CHEMOTHERAPY

An Open-label, Nonrandomized, Phase 1 Study to Evaluate the Safety and Pharmacokinetics of Belinostat in Patients with Relapsed/Refractory Solid Tumors or Hematological Malignancies Who Have Wild-Type, Heterozygous, and Homozygous UGT1A1*28 Genotypes

 

LIVER CANCER

A First-in-Human Phase I Trial to Determine the Safety and the Pharmacokinetic Profile of DSP-0337 in Patients with Advanced Solid Tumors

An Open-label, Nonrandomized, Phase 1 Study to Evaluate the Safety and Pharmacokinetics of Belinostat in Patients with Relapsed/Refractory Solid Tumors or Hematological Malignancies Who Have Wild-Type, Heterozygous, and Homozygous UGT1A1*28 Genotypes

LUNG

A Phase 1B/2 Study of VX15/2503 in Combination with Avelumab in Advanced Non-Small Cell Lung Cancer

 A Randomized Phase 2 Trial of AM0010 in Combination with Nivolumab vs. Nivolumab Alone as Second-Line Therapy in Subjects with Stage IV/Metastatic Wild Type Non-Small Cell Lung Cancer and Low Tumor Expression of PD-L1

A Randomized Phase 2 Trial of AM0010 in Combination with Pembrolizumab vs Pembrolizumab Alone as First-line Therapy in Patients with Metastatic Non-Small Cell Lung Cancer whose Tumors Have High PD-L1 Expression

A Phase I/II Clinical Study Evaluating the Safety and Effectiveness of BIO 300 Oral Suspension in Patients Receiving Chemoradiation Therapy for Non-Small Cell Lung Cancer (NSCLC)

Phase 2, Multi-Arm Study of Niraparib Administered Alone and in Combination with Pembrolizumab in Patients with Non-Small Cell Lung Cancer

Phase III Randomized Clinical Trial of Lurbinectedin (PM01183)/Doxorubicin (DOX) versus Cyclophosphamide(CTX), Doxorubicin(DOX) and Vincristine(VCR) (CAV) or Topotecan as Treatment in Patients with Small-Cell Lung Cancer (SCLC) Who Failed One Prior Platinum-containing Line (ATLANTIS Trial)

A randomized parallel group phase III trial of OSE 2101 as 2nd line after prior platinum-based chemotherapy failure or as 3rd line after platinum-failure and checkpoint inhibitor-failure, compared with standard treatment (docetaxel or pemetrexed) in HLA-A2 positive patients with locally advanced (IIIB) unsuitable for radiotherapy or metastatic Non-Small-Cell Lung Cancer. (OSE2101C301)

An Open-label, Nonrandomized, Phase 1 Study to Evaluate the Safety and Pharmacokinetics of Belinostat in Patients with Relapsed/Refractory Solid Tumors or Hematological Malignancies Who Have Wild-Type, Heterozygous, and Homozygous UGT1A1*28 Genotypes

LYMPHOMA

MDS (MYELODYSPLASTIC SNYDROME)

A Phase 3, Randomized, Open-Label, Crossover Study of AsTX727 (Cedazuridine and Decitabine Fixed-Dose Combination) vs IV Decitabine in Subjects with Myelodysplastic Syndromes (MDS) and Chronic Myelomonocytic Leukemia (CMML)

 A phase 3 Randomized Double-Blind Placebo-Controlled Study Investigating the Efficacy and Safety of Roxadustat (FG-4592) for Treatment of Anemia in Patients with Lower Risk Myelodysplastic Syndrome (MDS) with Low Red Blood Cell Transfusion (RBC) Transfusion Burden (LTB)

MELANOMA

Check back soon for upcoming trials.

MULTIPLE MYELOMA

A Phase 1a/1b Dose Escalation and Expansion Trial of TTI-622 in Patients with Advanced Relapsed or Refractory Lymphoma or Myeloma

A Phase 1b Study of SAR650984 (Anti-CD38 mAb) in Combination with Pomalidomide and Dexamethasone for the Treatment of Relapsed/Refractory Multiple Myeloma

A Randomized, Controlled, Open-Label, Phase 3 Study of Melflufen/Dexamethasone Compared with Pomalidomide/ Dexamethasone for Patients with Relapsed Refractory Multiple Myeloma who are Refractory to Lenalidomide

A Phase 3, Multicenter, Randomized, Double Blind Study of Bortezomib and Dexamethasone in Combination with Either Venetoclax or Placebo in Subjects with Relapsed or Refractory Multiple Myeloma Who are Sensitive or Naïve to Proteasome Inhibitors

A Phase 2 Study of Pomalidomide as a Replacement for Lenalidomide for Multiple Myeloma Patients Relapsed or Refractory to a Lenalidomide-Containing Combination Regimen

CA204008 ST: Prospective Research Assessment in Multiple Myeloma: an Observational Evaluation (PREAMBLE)

An Open-label, Nonrandomized, Phase 1 Study to Evaluate the Safety and Pharmacokinetics of Belinostat in Patients with Relapsed/Refractory Solid Tumors or Hematological Malignancies Who Have Wild-Type, Heterozygous, and Homozygous UGT1A1*28 Genotypes

MYELOFIBROSIS

A Phase 2 Dose Expansion of CPI-0610,a Small Molecule Inhibitor of BET Proteins, with and without Ruxolitinib in Patients with Myelofibrosis

NEUROENDOCRINE

Check back soon for upcoming trials.

OVARIAN

A First-in-Human Phase I Trial to Determine the Safety and the Pharmacokinetic Profile of DSP-0337 in Patients with Advanced Solid Tumors

An Open-label, Nonrandomized, Phase 1 Study to Evaluate the Safety and Pharmacokinetics of Belinostat in Patients with Relapsed/Refractory Solid Tumors or Hematological Malignancies Who Have Wild-Type, Heterozygous, and Homozygous UGT1A1*28 Genotypes

PAIN MANAGEMENT

Check back soon for upcoming trials.

PANCREATIC CANCER

A First-in-Human Phase I Trial to Determine the Safety and the Pharmacokinetic Profile of DSP-0337 in Patients with Advanced Solid Tumors

A Randomized Phase 3 Study of AM0010 in Combination with FOLFOX Compared with FOLFOX alone as a Second-line Therapy in Patients with Metastatic Pancreatic Cancer that has Progressed During or Following a First- Line Gemcitabine Containing Regimen

A Randomized Phase 3 Study of the Efficacy and Safety of Glufosfamide Compared with Fluorouracil (5-FU) in Patients with Metastatic Pancreatic Adenocarcinoma Previously Treated with Gemcitabine

An Open-label, Nonrandomized, Phase 1 Study to Evaluate the Safety and Pharmacokinetics of Belinostat in Patients with Relapsed/Refractory Solid Tumors or Hematological Malignancies Who Have Wild-Type, Heterozygous, and Homozygous UGT1A1*28 Genotypes

POLYCYTHEMIA VERA

Check back soon for upcoming trials.

PROSTATE CANCER

A First-in-Human Phase I Trial to Determine the Safety and the Pharmacokinetic Profile of DSP-0337 in Patients with Advanced Solid Tumors

An Extended/Phase 2, Multi-Center, Randomized, Open-Label Study to Evaluate the Safety and Tolerability of Proxalutamide (GT0918) in Subjects with Metastatic Castrate Resistant Prostate Cancer (mCRPC) who Failed Either Abiraterone or Enzalutamide

A Multinational, randomized, double-blind, placebo-controlled, phase III efficacy and safety study of ODM-201 in men with high risk non-metastatic castration-resistant prostate cancer

An Open-label, Nonrandomized, Phase 1 Study to Evaluate the Safety and Pharmacokinetics of Belinostat in Patients with Relapsed/Refractory Solid Tumors or Hematological Malignancies Who Have Wild-Type, Heterozygous, and Homozygous UGT1A1*28 Genotypes

RENAL CELL / KIDNEY CANCER

A First-in-Human Phase I Trial to Determine the Safety and the Pharmacokinetic Profile of DSP-0337 in Patients with Advanced Solid Tumors

An Open-label, Nonrandomized, Phase 1 Study to Evaluate the Safety and Pharmacokinetics of Belinostat in Patients with Relapsed/Refractory Solid Tumors or Hematological Malignancies Who Have Wild-Type, Heterozygous, and Homozygous UGT1A1*28 Genotypes

WALDENSTROM’S MACROGLOBULINEMIA

An Open-label, Nonrandomized, Phase 1 Study to Evaluate the Safety and Pharmacokinetics of Belinostat in Patients with Relapsed/Refractory Solid Tumors or Hematological Malignancies Who Have Wild-Type, Heterozygous, and Homozygous UGT1A1*28 Genotypes